What do hedge funds think about Synthetic Biologics Inc (NYSEAMEX:SYN)?
As stated earlier, at the end of the first quarter of 2015, a total of four hedge funds tracked by Insider Monkey held long positions in this stock, flat over the quarter. However, the last round of 13F filings showed that two investors closed their stakes and two other funds initiated new positions during the first three months. MSDC Management, led by Marc Lisker, Glenn Fuhrman and John Phelan, is the largest shareholder of Synthetic Biologics Inc (NYSEMK:SYN) with some 3.58 million shares worth $7.85 million. It is followed by Fred Knoll’s Knoll Capital Management with 3.40 million shares valued at $7.45 million.
Among the hedge funds with new positions in Synthetic Biologics are Israel Englander’s Millennium Management and Michael Platt & William Reeves’ Bluecrest Capital Management. Millennium Management owns 42,945 shares of the biotech company and Bluecrest Capital Management’s position stands at 24,251 shares, as of the end of March. On the other hand, Jeffrey Jay and David Kroin’s Great Point Partners and Ken Griffin’s Citadel Investment Group closed their stakes during the first quarter.
It is important to note that a positive result of this clinical trial could help the shares of Synthetic Biologics gain momentum in the upcoming months. Considering its impressive share performance in 2015, we consider that the stock is a ‘Buy’.